Universal Corporation

Fourth-quarter consolidated revenue was $715 million, up 2% year over year. Full-year consolidated revenue was $2.9 billion, down slightly from the prior year. Q4 operating loss was $15 million versus $43 million of operating income a year ago; full-year operating income was $169 million, down $64 million year over year. Q4 net loss attributable to Universal was $43 million versus $9 million of net income a year ago; full-year net income was $33 million versus $95 million last year. Tobacco segment revenue was $632 million in Q4, up 3%, and $2.6 billion for the year, down slightly; segment operating income was $27 million in Q4 versus $46 million a year ago and $212 million for the year versus $240 million. Ingredients revenue was $83 million in Q4 versus $90 million a year ago and $348 million for the year, up 3%; segment operating income was $2 million in Q4 versus $4 million a year ago and $3 million for the year versus $12 million. Inventory write-downs in tobacco operations were $43 million for fiscal 2026 versus $19 million in fiscal 2025. Net debt was $845 million at March 31, 2026, versus $817 million a year earlier, and liquidity availability totaled over $1.2 billion. For fiscal 2027, management expects uncommitted tobacco inventory to move into its 10% to 20% range and said it is early in the season but feels good about tobacco and optimistic ingredients can improve with better execution and volume.

Preston Wigner framed fiscal 2026 as a year of solid execution in a tougher market, with oversupply in certain tobacco styles and continued headwinds in ingredients. He emphasized that the core tobacco business remains durable and that Universal’s ingredients platform is still strategically important, but needs better commercial execution and operating efficiency. His tone was cautious but constructive, stressing that the company is entering fiscal 2027 with experience, geographic diversification, and a focus on maximizing tobacco and growing ingredients.

Steven Diel said the full-year results were mainly hurt by two items: the $41 million noncash goodwill impairment at Shank's and higher inventory write-downs in non-wrapper, dark air-cured tobacco. He highlighted that net debt was $845 million at March 31, 2026, up from $817 million, mainly because of working capital tied to a much larger tobacco crop, while liquidity availability was over $1.2 billion. He also said the company’s capital allocation strategy remains unchanged: support tobacco growth, increase the dividend, invest in ingredients, and return excess capital via share repurchases when appropriate.

Analysts focused on whether inventory would normalize in fiscal 2027, whether there is more write-down risk in dark air-cured tobacco, and how management views the setup in flue-cured, burley, and ingredients. Preston said uncommitted inventory, which was 27% as of March 31, should move into the 10% to 20% range during the fiscal year, and that the company feels comfortable after a thorough Q4 inventory review. On ingredients, he acknowledged persistent inflationary pressure and market headwinds, but said lower tariffs could ease customer pressure and create opportunities for higher volumes and better cost absorption.